Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.83Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 2.27%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and financial achievements, including successful trial results for lorundrostat, high physician interest, and strong financial backing. However, challenges remain, such as increased net loss and manageable concerns regarding hyperkalemia. Overall, the positive developments outweigh the challenges.Company Guidance
During the Mineralys First Quarter 2025 Earnings Conference Call, the company provided guidance on several key metrics and milestones. Mineralys reported achieving statistical significance and clinically meaningful results in the pivotal Launch-HTN and Advance-HTN trials, with a notable double-digit reduction in systolic blood pressure. They highlighted the favorable safety and tolerability profile of lorundrostat and its potential to transform hypertension treatment. Furthermore, Mineralys completed a $201.2 million public equity financing, contributing to a robust balance sheet with cash, cash equivalents, and investments totaling $343 million as of March 31, 2025. The company anticipates discussing trial results with the FDA in the fourth quarter of 2025, aiming for an NDA submission. Additionally, they reported a net loss of $42.2 million for the quarter, attributed to increased R&D and G&A expenses.Successful Pivotal Trials for Lorundrostat
The pivotal trials Launch-HTN and Advance-HTN achieved statistical significance and were clinically meaningful in efficacy endpoints, demonstrating a favorable safety and tolerability profile.
Publication and Presentation of Clinical Trial Results
Detailed results from the Advance-HTN trial were published in the New England Journal of Medicine and presented at the ACC '25 meeting, with Launch-HTN data accepted for a presentation at the European Society of Hypertension.
High Physician Interest in Lorundrostat
Survey results indicated that if approved, 95% of physicians are likely to prescribe lorundrostat for hypertension, specifically in third and fourth line positions.
Significant Financial Strength
Completion of a public equity financing raised gross proceeds of approximately $201.2 million before fees and expenses, contributing to a strong balance sheet.
New Appointment of Chief Commercial Officer
Eric Warren was appointed as Chief Commercial Officer, bringing 30 years of pharmaceutical industry experience.
---
MLYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MLYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $15.01 | $15.19 | +1.20% |
Feb 12, 2025 | $9.66 | $10.63 | +10.04% |
Nov 11, 2024 | $14.92 | $13.38 | -10.32% |
Aug 13, 2024 | $11.83 | $9.13 | -22.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mineralys Therapeutics, Inc. (MLYS) report earnings?
Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Mineralys Therapeutics, Inc. (MLYS) earnings time?
Mineralys Therapeutics, Inc. (MLYS) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLYS EPS forecast?
MLYS EPS forecast for the fiscal quarter 2025 (Q2) is -0.75.
---